Conyers provided British Virgin Islands and Cayman Islands legal advice to HUTCHMED (China) Limited (“HUTCHMED”) in connection with its HK$4.553 billion listing on the Main Board of The Stock Exchange of Hong Kong Limited of the shares of HUTCHMED involving a Hong Kong Public Offering and an International Offering. (Stock Code : 13)
This was the third listing of the shares of HUTCHMED, in addition to its current listings on Nasdaq and London AIM.
HUTCHMED is a biopharmaceutical company that develops, manufactures and sells pharmaceutical products. They offer drugs for autoimmune diseases and oncology treatment.
Partner Richard Hall, Associate Felicity Lee and Associate Michael Yu of Conyers’ Hong Kong office advised on the matter working alongside Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper UK LLP.